Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PMI vs TCMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TCMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

TCMD Overall Winner 6-Pillar Tally: PMI 1 – 5 TCMD Matrix Metrics: PMI 4 – 6 TCMD

As of Nov 19, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas TCMD carries 36.5/100 (SELL) at $25.99 (17.7x Forward P/E, 9.4% operating margin).

  • Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. TCMD 36.5/100 SELL), TCMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -248.1% operating margin) and revenue trajectory (+7.1% vs. +38.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PMI vs TCMD
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62
TCMD NASDAQ Head-to-Head Winner
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$25.99
-1.63% 1D
Market Cap $587.6M
TTM Revenue $356M
Forward P/E 17.7x
Beta / 30D Vol 0.99β · 52% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 30.0 Fund 40.0 Flow 66.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.1% over 20 days), RSI 57
RSI-14: 56.9 · SMA20: $25.39 · SMA50: $23.69

6-Pillar Scorecard Institutional Category Breakdown (PMI 1 – 5 TCMD)

Columns: Metric · PMI · TCMD
1. Valuation Multiples TCMD
Forward P/E N/M 17.7x
Trailing P/E 2.9x 25.5x
PEG Ratio N/M 17.79x
EV / Revenue 3.2x 1.5x
2. Growth & Scale PMI
Revenue Growth (YoY) +38.6% +7.1%
Earnings Growth (YoY) +0.0% -13.9%
TTM Revenue (USD) $6.3M $356M
Market Cap $17.1M $587.6M
3. Profitability & Quality TCMD
Gross Margin 18.6% 77.0%
Operating Margin -248.1% 9.4%
Net Profit Margin 0.0% 6.7%
Return on Equity (ROE) 0.0% 11.0%
4. Balance Sheet & Cash Flow TCMD
Cash Generation (TTM) -$17M $29M
Cash Flow Margin N/A 8.1%
Net Cash / Leverage $3.2M Net Debt $58M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TCMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 54.9% (15th %ile)
Put/Call OI Skew N/A 4.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat TCMD
OpEx & R&D Intensity N/A 67.6% of Rev ($241M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PMI (4) vs TCMD (6)
Institutional Metric PMI TCMD Criterion Row Edge
Market Capitalization
Scale
$17.1M $587.6M Larger Scale TCMD
Trailing P/E Ratio
Valuation
2.9x 25.5x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M 17.7x Lower Multiple TCMD
Revenue Growth (YoY)
Growth
+38.6% +7.1% Higher Growth PMI
Operating Margin (TTM)
Profitability
-248.1% 9.4% Higher Margin TCMD
Net Profit Margin
Profitability
0.0% 6.7% Higher Margin TCMD
Return on Equity (ROE)
Capital Efficiency
0.0% 11.0% Higher ROE TCMD
52-Week Range Position
Momentum
34% ($0–$18) 32% ($21–$38) Stronger Trend PMI
Beta / 30D Volatility
Risk Regime
54.06β · 134% Vol 0.99β · 52% Vol Lower Realized Risk TCMD
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 36.5 / 100 (SELL) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$6.3M $356M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.6% 77.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev 17.79x PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($3.2M Net Debt) $29M ($58M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCMD +46.22 pp
PMI: -34.58% · TCMD: +11.64%
3M Horizon PMI +87.15 pp
PMI: +96.26% · TCMD: +9.11%
6M Horizon PMI +3428.88 pp
PMI: +3439.33% · TCMD: +10.45%
1Y Horizon PMI +135.96 pp
PMI: +148.03% · TCMD: +12.07%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PMI Revenue TCMD Revenue PMI Op. Margin TCMD Op. Margin Margin Leader
FY2018 N/A $140M N/A 2.1% TCMD
FY2019 N/A $190M N/A 5.5% TCMD
FY2020 N/A $190M N/A -1.9% TCMD
FY2021 N/A $210M N/A -0.8% TCMD
FY2022 N/A $250M N/A -5.2% TCMD
FY2023 N/A $270M N/A 6.6% TCMD
FY2024 $0M $290M -312.3% 7.6% TCMD
FY2025 $0M $330M -268.4% 8.9% TCMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TCMD CONSOLIDATION
97d in phase · OBV DISTRIBUTION
Current IV 54.9%
IV Percentile 15th %ile
Put/Call OI Skew 4.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TCMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TCMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $587.6M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($241M)
90D Engineering Disclosures 0 Published

Investor FAQ PMI vs TCMD Key Questions & Quantitative Answers

As of Nov 19, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas TCMD carries 36.5/100 (SELL) at $25.99 (17.7x Forward P/E, 9.4% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. TCMD 36.5/100 SELL), TCMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -248.1% operating margin) and revenue trajectory (+7.1% vs. +38.6% YoY).

PMI leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with TCMD at +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PMI cumulative revenue shifted N/A while TCMD shifted +135.7%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus 67.6% of Rev ($241M) (0 disclosures) for TCMD.

TCMD screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas TCMD trades at 17.7x Forward P/E, 25.5x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus TCMD (11.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), a 4.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.99β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.